Monoclonal Antibodies FAQ
Tips and technical resources to kickstart your experiments and keep them moving forward, including concentration calculations, centrifuges, sample management, and more.
Monoclonal antibodies (mAbs) are identical antibodies produced by a single clone of B cells, targeting a specific epitope. Polyclonal antibodies are mixtures from multiple clones, and the resulting mixture will be recognizing multiple epitopes on an antigen. This makes mAbs highly specific and experiments utilizing them highly reproducible in research settings.
Select antibodies validated for your specific application and target species by reviewing datasheets or consulting the supplier's technical support to ensure compatibility with your assay’s format and sample type.
Yes, AAA Biotech offers monoclonals for common and rare species in multiple conjugated forms, enabling use with diverse sample types, including uncommon tissues or organisms.
Mouse mAbs are derived entirely from mice. Humanized mAbs combine mouse antigen-binding regions with human antibody frameworks to reduce immunogenicity. Fully human mAbs are entirely human in sequence, minimizing immune reactions in therapeutic contexts.
Review the supplier’s validation data, such as ELISA, Western blot, or flow cytometry results. Cross-reactivity tests against related proteins are usually documented in datasheets or validation reports.
Evaluate based on antibody validation for your applications, reproducibility, lot-to-lot consistency, supplier technical support, and available characterization data like purity profiles or binding affinities.
Request datasheets with application validations (e.g., ELISA, WB, IHC), specificity assessments, purity analysis by SDS-PAGE, and any available batch consistency data.
Many vendors, including AAA Biotech, may offer small or trial sample volumes to evaluate antibody performance before bulk purchase. Contact the supplier sales/support for availability.
Store at recommended temperatures, typically -20°C or 4°C for short-term, and avoid repeated freeze-thaw cycles. Use aliquots and follow supplier storage guidelines precisely to preserve antibody function.
10. What are common issues with lot-to-lot variability, and how can I avoid them? Variability arises from production inconsistencies. Use monoclonal antibodies from suppliers with stringent quality control and batch characterization. Testing new lots before full experiments helps maintain reproducibility.
Choose antibodies validated for those specific applications. Consult datasheets detailing tested techniques and conditions. Optimizing assay conditions as per recommendations also improves outcomes.
Contact the supplier immediately for replacement or technical support. Store antibodies as instructed and avoid improper handling to prevent degradation.
Use well-characterized, validated antibodies from reliable sources. Maintain consistent storage and handling. Document lot numbers and test reagents periodically to confirm stable performance.
Expect access to technical datasheets, troubleshooting guides, application advice, and responsive customer support for assay optimization and product issues.
Provide training on antibody properties, storage, assay selection, experiment setup, and troubleshooting. Utilize supplier technical resources and standard operating procedures for consistency.
There is no broad FDA ban on monoclonal antibodies. Some specific antibodies or products may be withdrawn for safety or efficacy reasons, but mAbs remain widely approved and used therapies.
Potential downsides include immunogenic reactions, production cost, and limited effectiveness against some targets. Infusion reactions and side effects require careful clinical monitoring.
Monoclonal antibodies treat various cancers, including lymphoma, leukemia, breast cancer, lung cancer, and colorectal cancer, by targeting tumor-specific antigens or immune checkpoints.
They include murine (mouse), chimeric, humanized, and fully human antibodies, differing in the origin and structure of their protein sequences.
Examples include trastuzumab (Herceptin), rituximab, pembrolizumab, and muromonab-CD3, used in cancer and autoimmune conditions.
Patients requiring targeted cancer therapy, autoimmune disease treatment, or immune modulation may receive mAb treatments, based on clinical evaluation.
Monoclonal antibodies are artificially produced in labs using cloned immune cells but mimic the natural antibody structure and function.
Monoclonal antibodies like erenumab target the CGRP pathway to prevent migraine attacks by blocking specific receptors involved in pain signaling.
Contact us
Our expert team is here to help with your scientific queries and experiment needs via Chat, email, or phone. Let's make progress together.